Related Experiment Videos
Multiple myeloma: significance of plasmablastic subtype in morphological classification
Abstract:
We classified 100 cases of myeloma before chemotherapy as mature (28), intermediate (38), immature (19), or plasmablastic (15). The plasmablastic group had an estimated median survival (Kaplan-Meier method) of ten months, compared to 35 months for the other types (P less than .05). Decreased survival in the plasmablastic group was due to more frequent deaths in the first six months. There were no significant differences in survival among the mature, intermediate, and immature groups or among patients with different morphological grade or asynchrony scores. The plasmablastic myeloma group had more frequent renal insufficiency and higher plasma cell labeling indices, which may have contributed to the shorter survival.
Insights
Plasmablastic myeloma, a subtype identified before chemotherapy, is associated with significantly shorter survival. This finding highlights the importance of early classification for predicting patient outcomes in myeloma.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Myeloma classification is crucial for prognosis.
- Pre-chemotherapy morphological classification can inform treatment strategies.
Purpose of the Study:
- To classify 100 myeloma cases before chemotherapy.
- To evaluate the prognostic significance of different myeloma subtypes, particularly plasmablastic myeloma.
Main Methods:
- Morphological classification of 100 myeloma cases into mature, intermediate, immature, and plasmablastic subtypes.
- Kaplan-Meier survival analysis to compare median survival between subtypes.
Main Results:
- Plasmablastic myeloma (15 cases) showed a median survival of 10 months, significantly shorter than other subtypes (35 months).
- Increased early mortality was observed in the plasmablastic group.
- Plasmablastic myeloma was linked to higher rates of renal insufficiency and plasma cell labeling indices.
Conclusions:
- Plasmablastic myeloma is an aggressive subtype with poor prognosis.
- Early identification of plasmablastic myeloma may guide intensified treatment approaches.
- Further research into the mechanisms driving poor survival in plasmablastic myeloma is warranted.